Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Open-Labeled, Repeat Dose, Safety and Efficacy Study of Renal Autologous Cell Therapy (REACT) in Subjects With Type 1 or 2 Diabetes and Chronic Kidney Disease (REGEN-007)

Next Previous
Trial Profile

A Phase 2, Randomized, Open-Labeled, Repeat Dose, Safety and Efficacy Study of Renal Autologous Cell Therapy (REACT) in Subjects With Type 1 or 2 Diabetes and Chronic Kidney Disease (REGEN-007)

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rilparencel (Primary)
  • Indications Diabetic nephropathies; Renal failure
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms REGEN-007
  • Sponsors ProKidney

Most Recent Events

  • 17 Mar 2025 According to Prokidney media release, Full data from Group 1 of the Phase 2 REGEN-007 study are expected in Q2 2025 and will comprise approximately 20 patients who have received two rilparencel injections, with an average follow-up of approximately 18 months.
  • 12 Nov 2024 According to Prokidney media release, In late Oct, company presented poster presentation at the American Society of Nephrology's (ASN) Kidney Week. This included a poster presentation in the late-breaking clinical trial session on the Phase 2 REGEN-007 study.
  • 14 Oct 2024 According to Prokidney media release, company announced that the Company will present poster of this clinical trial, at the upcoming American Society of Nephrology (ASN) Kidney Week being held on October 23-27, 2024, in San Diego, CA.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top